News

Filter

New schizophrenia drug Abilify to lead the market by 2016

New schizophrenia drug Abilify to lead the market by 2016

29-12-2013

Long-acting depot therapy Abilify Maintena (aripiprazole) will become the leading injectable schizophrenia…

AbilifyAbilify MaintenaFinancialGlobalLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceutical

Roche/Chugai's bitopertin set to garner $1.5 billion sales in 2022

23-08-2013

Swiss drug major Roche (ROG: SIX) and its majority-owned Japanese affiliate Chugai's glycine transporter-1…

AbilifyAbilify MaintenabitopertinChugai PharmaceuticalEuropeGenericsJanssenLundbeckMarkets & MarketingNeurologicalNorth AmericaOtsukaPaliperidonePharmaceuticalRocheSeroquelZyprexa

Otsuka and Lundbeck expand current Abilify collaboration

07-03-2013

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) and Denmark-based CNS specialist Lundbeck (LUND:…

AbilifyAbilify MaintenabrexpiprazoleEuropeLicensingLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceutical

COMPANY SPOTLIGHT

Menarini

Back to top